Amyloidotic Cardiomyopathy: Multidisciplinary Approach to Diagnosis and Treatment

Heart Failure Clinics

Volumn 7, Issue 3, 2011, Pages 385-393

  Seldin, David C ^a,b   Berk, John L ^a,c   Sam, Flora ^a   Sanchorawala, Vaishali ^a,b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON MEDICAL CENTER   (United States)

^c Department of Medicine   (United States)

Author keywords

Amyloidosis; Autologous stem cell transplantation; Biomarkers; Cardiomyopathy; Immunoglobulin light chain; Matrix metalloproteinase; Transthyretin

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; AMYLOID; AMYLOID A PROTEIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BORTEZOMIB; BRAIN NATRIURETIC PEPTIDE; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; DEXAMETHASONE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOPAMINE; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN LIGHT CHAIN; IMMUNOMODULATING AGENT; LENALIDOMIDE; LOOP DIURETIC AGENT; MELPHALAN; METOLAZONE; PLERIXAFOR; POMALIDOMIDE; PREALBUMIN; PREDNISONE; SERUM AMYLOID A; SPIRONOLACTONE; THALIDOMIDE; TROPONIN; TROPONIN T;

AMYLOIDOSIS; ANASARCA; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BIRTH DEFECT; BRADYCARDIA; CONGESTIVE HEART FAILURE; CORTICOSTEROID THERAPY; DRUG MEGADOSE; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FAMILIAL AMYLOID POLYNEUROPATHY; FAMILIAL AMYLOIDOSIS; FLOW CYTOMETRY; GENE MUTATION; GENE SEQUENCE; GENETIC POLYMORPHISM; HEART AMYLOIDOSIS; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART MUSCLE BIOPSY; HEART TRANSPLANTATION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; IMMUNOELECTRON MICROSCOPY; IMMUNOELECTROPHORESIS; IMMUNOHISTOCHEMISTRY; ISOELECTRIC FOCUSING; KIDNEY AMYLOIDOSIS; LEUKAPHERESIS; MASS SPECTROMETRY; MULTIPLE MYELOMA; NEPHROTIC SYNDROME; NEUROPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PLASMA CELL DYSCRASIA; PLEURA EFFUSION; PROTEIN ANALYSIS; REVIEW; RNA INTERFERENCE; SENILE AMYLOIDOSIS; SIDE EFFECT; SODIUM RESTRICTION; UREMIA;

AMYLOID; AMYLOIDOSIS; BIOLOGICAL MARKERS; BIOPSY; CARDIOMYOPATHIES; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DIAGNOSIS, DIFFERENTIAL; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; HUMANS; MYOCARDIUM; NATRIURETIC PEPTIDE, BRAIN; SEVERITY OF ILLNESS INDEX; TROPONIN T; VENTRICULAR FUNCTION, LEFT;

EID: 79960220799     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2011.03.009     Document Type: Review

References (40)

1. Girnius S., Dember L., Doros G., et al. The changing face of AA amyloidosis: a single centre experience. Amyloid 2010, 17(Suppl 1):72.
2. Connors L.H., Richardson A.M., Theberge R., et al. Tabulation of transthyretin (TTR) variants as of 1/1/2000. Amyloid 2000, 7:54.
3. Gustavsson A., Jahr H., Tobiassen R., et al. Amyloid fibril composition and transthyretin gene structure in senile systemic amyloidosis. Lab Invest 1995, 73:703.
4. Ruberg F.L., Appelbaum E., Davidoff R., et al. Diagnostic and prognostic utility of cardiovascular magnetic resonance imaging in light-chain cardiac amyloidosis. Am J Cardiol 2009, 103:544.
5. Hawkins P.N., Aprile C., Capri G., et al. Scintigraphic imaging and turnover studies with iodine-131 labeled serum amyloid P component in systemic amyloidosis. Eur J Nucl Med 1998, 25:701.
6. Libbey C.A., Skinner M., Cohen A.S. Use of abdominal fat tissue aspirate in the diagnosis of systemic amyloidosis. Arch Intern Med 1983, 143:1549.
7. Dubrey S.W., Cha K., Skinner M., et al. Familial and primary (AL) cardiac amyloidosis: echocardiographically similar diseases with distinctly different clinical outcomes. Heart 1997, 78:74. [see comments].
8. Ng B., Connors L.H., Davidoff R., et al. Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis. Arch Intern Med 2005, 165:1425.
9. Brenner D.A., Jain M., Pimentel D.R., et al. Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ Res 2004, 94:1008.
10. Liao R., Jain M., Teller P., et al. Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts. Circulation 2001, 104:1594.
11. Shi J., Guan J., Jiang B., et al. Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway. Proc Natl Acad Sci U S A 2010, 107:4188.
12. Biolo A., Ramamurthy S., Connors L.H., et al. Matrix metalloproteinases and their tissue inhibitors in cardiac amyloidosis: relationship to structural, functional myocardial changes and to light chain amyloid deposition. Circ Heart Fail 2008, 1:249.
13. Obici L., Perfetti V., Palladini G., et al. Clinical aspects of systemic amyloid diseases. Biochim Biophys Acta 2005, 1753:11.
14. Gertz M.A., Comenzo R., Falk R.H., et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 2005, 79:319.
15. Palladini G., Campana C., Klersy C., et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 2003, 107:2440.
16. Dispenzieri A., Gertz M.A., Kyle R.A., et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 2004, 22:3751.
17. Dispenzieri A., Kyle R.A., Gertz M.A., et al. Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet 2003, 361:1787.
18. Apridonidze T., Comenzo R., Hoffman J., et al. Troponin as a prognostic marker in cardiac amyloidosis. Amyloid 2010, 17:167a.
19. Gertz M., Merlini G. Definition of organ involvement and response to treatment in AL amyloidosis: an updated consensus opinion. Amyloid 2010, 17:48a.
20. Jaccard A., Moreau P., Leblond V., et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 2007, 357:1083.
21. Skinner M., Sanchorawala V., Seldin D.C., et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004, 140:85.
22. Goldsmith Y.B., Liu J., Chou J., et al. Frequencies and types of arrhythmias in patients with systemic light-chain amyloidosis with cardiac involvement undergoing stem cell transplantation on telemetry monitoring. Am J Cardiol 2009, 104:990.
23. Meier-Ewert H.K., Sanchorawala V., Berk J., et al. Regression of cardiac wall thickness following chemotherapy and stem-cell transplantation for AL amyloidosis. Amyloid 2010, 17(Suppl 1):150.
24. Palladini G., Perfetti V., Obici L., et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 2004, 103:2936.
25. Specter R., Sanchorawala V., Seldin D.C., et al. Kidney dysfunction during lenalidomide treatment for AL amyloidosis. Nephrol Dial Transplant 2011, 26:881.
26. Nowis D., Maczewski M., Mackiewicz U., et al. Cardiotoxicity of the anticancer therapeutic agent bortezomib. Am J Pathol 2010, 176:2658.
27. Connors L.H., Prokaeva T., Lim A., et al. Cardiac amyloidosis in African Americans: comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis. Am Heart J 2009, 158:607.
28. Dubrey S.W., Davidoff R., Skinner M., et al. Progression of ventricular wall thickening after liver transplantation for familial amyloidosis. Transplantation 1997, 64:74.
29. Liepnieks J.J., Benson M.D. Progression of cardiac amyloid deposition in hereditary transthyretin amyloidosis patients after liver transplantation. Amyloid 2007, 14:277.
30. Berk J.L., Keane J., Seldin D.C., et al. Persistent pleural effusions in primary systemic amyloidosis: etiology and prognosis. Chest 2003, 124:969.
31. Gertz M.A., Falk R.H., Skinner M., et al. Worsening of congestive heart failure in amyloid heart disease treated by calcium channel-blocking agents. Am J Cardiol 1985, 55:1645.
32. Gertz M.A., Skinner M., Connors L.H., et al. Selective binding of nifedipine to amyloid fibrils. Am J Cardiol 1985, 55:1646.
33. Pollak A., Falk R.H. Left ventricular systolic dysfunction precipitated by verapamil in cardiac amyloidosis. Chest 1993, 104:618.
34. Rubinow A., Skinner M., Cohen A.S. Digoxin sensitivity in amyloid cardiomyopathy. Circulation 1981, 63:1285.
35. Hosenpud J.D., Uretsky B.F., Griffith B.P., et al. Successful intermediate-term outcome for patients with cardiac amyloidosis undergoing heart transplantation: results of a multicenter survey. J Heart Transplant 1990, 9:346.
36. Hosenpud J.D., DeMarco T., Frazier O.H., et al. Progression of systemic disease and reduced long-term survival in patients with cardiac amyloidosis undergoing heart transplantation. Follow-up results of a multicenter survey. Circulation 1991, 84:III338.
37. Dey B.R., Chung S.S., Spitzer T.R., et al. Cardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failure. Transplantation 2010, 90:905.
38. Lacy M.Q., Dispenzieri A., Hayman S.R., et al. Autologous stem cell transplant after heart transplant for light chain (AL) amyloid cardiomyopathy. J Heart Lung Transplant 2008, 27:823.
39. Modesto K.M., Dispenzieri A., Cauduro S.A., et al. Left atrial myopathy in cardiac amyloidosis: implications of novel echocardiographic techniques. Eur Heart J 2005, 26:173.
40. Feng D., Syed I.S., Martinez M., et al. Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis. Circulation 2009, 119:2490.